Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor ...

SGLT2 inhibitors are already used to treat diabetes and chronic kidney disease. This study helps explain why patients taking ...

A new study published in the Journal of American Medical Association showed that when renal protection is a primary therapeutic objective, starting treatment with an SGLT2 inhibitor (SGLT2i) ...

SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the clinical impact.

A fast-aging fish is giving scientists a rare, accelerated look at how kidneys grow old—and how a common drug may slow that ...

Observational data point to the scope of opportunity that lies in GLP-1 drugs, SGLT2 inhibitors, and nonsteroidal MRAs.

The American Heart Association released its 2026 Heart Disease and Stroke Statistics Update, and a reminder that heart ...

DEAR DR. ROACH: Outside of limiting your salt intake, avoiding potassium and phosphates, and hydrating properly, is there ...

ProKidney Corp. targets diabetic CKD with Rilparencel and expects Q2 2027 eGFR slope data for accelerated approval. Find out ...

Vitamin D3 may be one exception as it is important to prevent and treat osteoporosis for those who are at risk. While I often ...

Natalie McCormick, PhD, of the Rheumatology and Allergy Clinical Epidemiology Research (RACER) Center within the Division of ...

Patients with a heart failure history and preserved ejection fraction appeared to benefit ...